Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GnRH antagonist + recombinant follicle-stimulating hormone
- Development stage
- Unknown
- Lead developer
- Universitair Ziekenhuis Brussel
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
This intervention refers to a specific ovarian stimulation protocol evaluated by Universitair Ziekenhuis Brussel for women undergoing IVF or ICSI. The protocol involves the administration of a GnRH antagonist (such as ganirelix or cetrorelix) for three consecutive days at the start of the menstrual cycle (days 2-4) to suppress endogenous gonadotropins before initiating standard ovarian stimulation with recombinant follicle-stimulating hormone (rFSH). GnRH antagonists work by competitively blocking the GnRH receptors in the pituitary gland, preventing premature luteinizing hormone (LH) surges. Recombinant FSH is then used to stimulate the development of multiple ovarian follicles. This specific pretreatment approach aims to improve follicular synchrony and increase the number of oocytes retrieved in patients with various causes of infertility, including polycystic ovary syndrome (PCOS) and endometriosis.
- Other names
- ovarian stimulation-Universitair Ziekenhuis Brussel-infertilityGnRH antagonist pretreatment protocolAdministration of a GnRH Antagonist During 3 Days at Initiation of the Cycle: Impact on the Stimulation in IVF/ICSI
02
Targets
FSHR (Follicle-stimulating hormone receptor)GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on GnRH antagonist + recombinant follicle-stimulating hormone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GnRH antagonist + recombinant follicle-stimulating hormone.